These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29024542)

  • 21. Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin.
    Washington C; Hou E; Hughes N; Berner B
    Am J Health Syst Pharm; 2006 Apr; 63(7):653-6. PubMed ID: 16554289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole.
    de Kanter CT; Colbers AP; Blonk MI; Verweij-van Wissen CP; Schouwenberg BJ; Drenth JP; Burger DM
    J Antimicrob Chemother; 2013 Jun; 68(6):1415-22. PubMed ID: 23429642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability of a controlled-release cyclobenzaprine tablet and influence of a high fat meal on bioavailability.
    Gai MN; Costa E; Arancibia A
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):269-74. PubMed ID: 19356393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative bioavailability of diclofenac potassium from softgel capsule versus powder for oral solution and immediate-release tablet formulation.
    Bende G; Biswal S; Bhad P; Chen Y; Salunke A; Winter S; Wagner R; Sunkara G
    Clin Pharmacol Drug Dev; 2016 Jan; 5(1):76-82. PubMed ID: 27119581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
    Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
    Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects.
    Lau YY; Gu W; Lin T; Song D; Yu R; Scott JW
    J Clin Pharmacol; 2016 May; 56(5):559-66. PubMed ID: 26272586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of omeprazole on the pharmacokinetics of itraconazole.
    Jaruratanasirikul S; Sriwiriyajan S
    Eur J Clin Pharmacol; 1998 Apr; 54(2):159-61. PubMed ID: 9626921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers.
    Cullberg M; Arfvidsson C; Larsson B; Malmgren A; Mitchell P; Wählby Hamrén U; Wray H
    Drugs R D; 2018 Jun; 18(2):149-159. PubMed ID: 29856004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers.
    Hasan A; Abul Kalam Azad M; Ullah MA; Mahbub Latif AH; Hasnat A
    Int J Clin Pharmacol Ther; 2009 Mar; 47(3):215-21. PubMed ID: 19281731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of food on the bioavailability of palbociclib.
    Ruiz-Garcia A; Plotka A; O'Gorman M; Wang DD
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):527-533. PubMed ID: 28204912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
    Cox DS; Allred A; Zhou Y; Infante JR; Gordon MS; Bendell J; Jones S; Burris H; Orford K
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):287-94. PubMed ID: 27136909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
    Infante JR; Ramanathan RK; George D; Tan E; Quinlan M; Liu A; Scott JW; Sharma S
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):729-37. PubMed ID: 25648347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.
    Giri N; Lam LH; LaBadie RR; Krzyzaniak JF; Jiang H; Hee B; Liang Y; Shaik MN
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1249-1260. PubMed ID: 29086063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
    Winston A; Back D; Fletcher C; Robinson L; Unsworth J; Tolowinska I; Schutz M; Pozniak AL; Gazzard B; Boffito M
    AIDS; 2006 Jun; 20(10):1401-6. PubMed ID: 16791014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
    Sarantopoulos J; Goel S; Chung V; Munster P; Pant S; Patel MR; Infante J; Tawbi H; Becerra C; Bruce J; Kabbinavar F; Lockhart AC; Tan E; Yang S; Carlson G; Scott JW; Sharma S
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):921-927. PubMed ID: 27681579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients.
    Mahadevan D; Mita M; Richards D; McClay E; Heist RS; Kumar A; Sundararajan S; Naing A
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):681-688. PubMed ID: 28289865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects.
    Xu H; O'Gorman M; Boutros T; Brega N; Kantaridis C; Tan W; Bello A
    J Clin Pharmacol; 2015 Jan; 55(1):104-13. PubMed ID: 24990113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.